Form 8-K - Current report:
SEC Accession No. 0000950170-25-063539
Filing Date
2025-05-05
Accepted
2025-05-05 16:10:07
Documents
13
Period of Report
2025-05-05
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K rlay-20250505.htm   iXBRL 8-K 42946
2 EX-99.1 rlay-ex99_1.htm EX-99.1 146068
3 GRAPHIC img175089203_0.jpg GRAPHIC 7375
  Complete submission text file 0000950170-25-063539.txt   320106

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT rlay-20250505.xsd EX-101.SCH 23863
15 EXTRACTED XBRL INSTANCE DOCUMENT rlay-20250505_htm.xml XML 4526
Mailing Address 399 BINNEY STREET 2ND FLOOR CAMBRIDGE MA 02139
Business Address 399 BINNEY STREET 2ND FLOOR CAMBRIDGE MA 02139 617-370-8837
Relay Therapeutics, Inc. (Filer) CIK: 0001812364 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39385 | Film No.: 25913018
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)